SINTX Technologies (NASDAQ:SINT) shares are trading higher after the company announced the SARS-CoV-2 virus was inactivated in a lab study when exposed to its sintered silicon nitride powder.
As the COVID-19 pandemic continues throughout the world, vaccine and treatment companies continue to report on their findings. Equities have been increasingly volatile following the resurgence of cases as the United States begins to reopen.
SINTX Technologies is a commercial biomaterial company, focuses on using its silicon nitride technology platform to develop, manufacture and sell a range of medical devices. It derives its revenue primarily from the sale of spinal fusion and fixation devices and related products used in the treatment of spine disorders.
SINTX Technologies was trading 208% higher at $2.38 at the time of publication on Monday. The stock has a 52-week high of $4.39 and a 52-week low of 28 cents.